Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

H Mohammad; K Madsen; O Graumann; A C Loya; N V Jensen; R H Dahlrot

doi:10.1016/j.eucr.2021.101880

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

Urol Case Rep. 2021 Oct 8:40:101880. doi: 10.1016/j.eucr.2021.101880. eCollection 2022 Jan.

Authors

H Mohammad¹, K Madsen^{2

3}, O Graumann^{4

5}, A C Loya^{6

7}, N V Jensen¹, R H Dahlrot^{1

5}

Affiliations

¹ Department of Oncology, Odense University Hospital, Odense, Denmark.
² Department of Pathology, Odense University Hospital, Odense, Denmark.
³ Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.
⁴ Department of Radiology, Odense University Hospital, Odense, Denmark.
⁵ Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁶ Department of Pathology, Rigshospitalet, Copenhagen, Denmark.
⁷ Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Abstract

Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

Keywords: Metanephric adenoma; Oncology; Renal tumour; Tyrosine kinase inhibitor.

Publication types

Case Reports